These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 9788333)
1. Japanese abandon domestic trials. Saegusa A Nat Biotechnol; 1998 Oct; 16(10):898-9. PubMed ID: 9788333 [No Abstract] [Full Text] [Related]
2. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860 [TBL] [Abstract][Full Text] [Related]
3. Clinical trials registration efforts gain some ground. Zielinski SL J Natl Cancer Inst; 2005 Mar; 97(6):410-1. PubMed ID: 15769999 [No Abstract] [Full Text] [Related]
4. [Why multi-national clinical trials now?--Industry perspective]. Miki S Gan To Kagaku Ryoho; 2007 Feb; 34(2):293-6. PubMed ID: 17301547 [TBL] [Abstract][Full Text] [Related]
5. International working group standardizes drug testing requirements in the elderly. Am J Hosp Pharm; 1994 Nov; 51(22):2776, 2779. PubMed ID: 7856598 [No Abstract] [Full Text] [Related]
6. [Participation to international registration trials--from the investigator's standpoint]. Ohtsu A Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548 [TBL] [Abstract][Full Text] [Related]
7. Neonatal drug trials: impact of EU and US paediatric regulations. Pansieri C; Bonati M; Choonara I; Jacqz-Aigrain E Arch Dis Child Fetal Neonatal Ed; 2014 Sep; 99(5):F438. PubMed ID: 24792777 [No Abstract] [Full Text] [Related]
8. The International Conference on Harmonization common technical document--global submission format? Molzon JA Food Drug Law J; 2005; 60(3):447-51. PubMed ID: 16304749 [No Abstract] [Full Text] [Related]
9. Globalization of clinical research by the pharmaceutical industry. Shah S Int J Health Serv; 2003; 33(1):29-36. PubMed ID: 12641261 [TBL] [Abstract][Full Text] [Related]
10. [Operational aspect of participation in the multi-national clinical trials from the foreign pharmaceutical company's standpoint]. Namazu K Gan To Kagaku Ryoho; 2007 Feb; 34(2):328-30. PubMed ID: 17301556 [TBL] [Abstract][Full Text] [Related]
11. [Regulatory status of safety pharmacology. Implications]. Barbier A; Caille D Therapie; 2002; 57(2):104-8. PubMed ID: 12185955 [TBL] [Abstract][Full Text] [Related]
12. A critique of emerging European legislation in the pharmaceutical industry: a clinical trials analysis. Murray E; McAdam R; Burke MT Int J Health Care Qual Assur Inc Leadersh Health Serv; 2004; 17(7):389-93. PubMed ID: 15552394 [TBL] [Abstract][Full Text] [Related]
14. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase]. Kock M; Thomsen MK Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820 [TBL] [Abstract][Full Text] [Related]
15. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role]. Ainsworth MA Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819 [TBL] [Abstract][Full Text] [Related]
17. Clinical investigations: taking a global approach, part II. Schaefer JF; Jessup G Med Device Technol; 1993 Dec; 4(10):32-6. PubMed ID: 10146566 [No Abstract] [Full Text] [Related]